Related Experiment Video
Updated: Jun 19, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.5K
GLP-1 RAs: The newest powerhouse in metabolic medicine
The Nurse Practitioner
|July 25, 2024
Summary
Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed type 2 diabetes care. This review covers available GLP-1 RAs, their benefits, and challenges like cost and access.
Area of Science:
- Pharmacology and Endocrinology
- Metabolic Diseases
Background:
- Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) represent a significant advancement in managing type 2 diabetes mellitus.
- This drug class also demonstrates efficacy in treating associated conditions such as obesity and cardiovascular disease.
Purpose of the Study:
- To provide a comprehensive overview of the current landscape of GLP-1 RAs.
- To detail their mechanisms of action, approved indications, and potential adverse effects.
- To offer practical guidance for healthcare providers managing patients on these therapies.
Main Methods:
- Literature review of available GLP-1 receptor agonists.
- Analysis of pharmacological profiles, clinical trial data, and post-marketing surveillance.
- Synthesis of information on efficacy, safety, and accessibility.
Main Results:
- GLP-1 RAs have revolutionized type 2 diabetes treatment, offering significant benefits for glycemic control and weight management.
- Established agents and newer formulations continue to expand therapeutic options.
- Barriers to care, including drug cost and availability, remain significant challenges.
Conclusions:
- GLP-1 RAs are a cornerstone therapy for type 2 diabetes and related comorbidities.
- Understanding their diverse profiles is crucial for optimizing patient outcomes.
- Addressing access barriers is essential for broader clinical implementation.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
01:06Oral Hypoglycemic Agents: Glinides
151
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
151
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
01:17Oral Hypoglycemic Agents: Sulfonylureas
199
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
199